UA151924U - Application of the infusion drug sorbilact for normalization of hematological parameters of operated patients with left lung cancer after left-sided pulmonectomy - Google Patents

Abstract

The application of the infusion complex preparation Sorbilact with multifunctional action is used to normalize hematological parameters in operated lung cancer patients after surgery for left-sided pneumonectomy during the early postoperative period.

Description

The useful model belongs to the field of medicine, namely, it concerns the use of the multi-functional infusion complex drug Sorbilact for the normalization of hematological parameters of operated patients with left lung cancer after left-sided pulmonectomy in the early postoperative period.

The relevance of the subject of the useful model is connected with the increase in the incidence of cancer of the left lung and the increase in the number of operations for total removal of the left lung.

Oncology patients with left lung cancer, who underwent left-sided pulmonectomy, develop changes in hematological indicators that worsen the course of the early postoperative period and lead to complications that are the cause of mortality.

It is impossible to treat postoperative complications without correcting the hematological parameters of operated patients with cancer of the left lung.

The use of the multi-functional infusion complex drug Sorbilact for the normalization of hematological parameters of operated patients with left lung cancer after left-sided pulmonectomy in the early postoperative period is relevant and necessary in the surgical treatment of oncological patients after thoracic operations.

Ringer-Locke solution for intravenous infusions of 800.0 ml per day was used as a comparison drug. Composition of Ringer-Lock solution: sodium chloride - 9.0 g, sodium bicarbonate - 0.2 g, calcium chloride - 0.2 g, potassium chloride - 0.2 g, glucose - 1.0 g, water for injections - up to 1 liter.

In contrast to the Ringer-Lock solution, in the infusion drug Sorbilact, the main active substances are sorbitol and the alkalizing agent sodium lactate, which normalizes the acid-base state of the body.

Sorbilact - an infusion preparation, which includes: sorbitol - 200.0 g, sodium lactate - 19.0 g, sodium chloride - 6.0 g, calcium chloride - 0.1 g, potassium chloride - 0.3 g, magnesium chloride - 0.2 g, water for injections - up to 1.0 liters.

Ionic composition of the drug: sodium ion - 6.395 mg/ml - 278.16 mmol/l; potassium ion - 0.157 mg/ml - 4.02 mmol/l; calcium ion - 0.036 mg/ml - 0.90 mmol/l; magnesium ion - 0.051 mg/ml - 2.10 mmol/l; chlorine ion - 3.995 mg/ml - 112.69 mmol/l; lactate ion - 15.635 mg/ml - 175.52 mmol/l; pH - 6.0-7.6.

The calorie content of Sorbilact is 656 kcal (2736 kJ) per 800.0 milliliters of infusion

From the solution. Sorbilact is a clear liquid in bottles of 200.0 and 400.0 ml.

Complex infusion drug Sorbilact of multifunctional action was created and developed at the State Institution "Institute of Blood Pathology and Transfusion Medicine

of the National Academy of Medical Sciences of Ukraine", Lviv.

The instructions for the medical use of the infusion drug Sorbilact were approved by the order of the Ministry of Health of Ukraine No. 629 of March 21, 2019, registration certificate OA /2401/01/01.

The basis of a useful model is the task of increasing the therapeutic effectiveness of infusion therapy using the complex drug Sorbilact of multifunctional action in oncological patients with left lung cancer after left-sided pulmonectomy to normalize the hematological indicators of operated patients in the early postoperative period, reduce the duration of treatment of operated patients, reduce the number of bed- days

The task is solved by the fact that immediately after the operation, intravenous infusions of the complex drug Sorbilact of multifunctional action are used at the rate of 600.0 ml per day at a rate of 30 drops per minute for 5 days.

In cancer patients, in order to establish a clinical diagnosis, in addition to x-ray examination of the chest organs, a bronchoscopic examination was performed using a flexible bronchoscope with tumor biopsy, as well as a computer examination of the chest cavity organs.

In order to establish the therapeutic effectiveness of the use of the infusion drug Sorbilact for the normalization of hematological indicators of patients operated on for left lung cancer after left-sided pulmonectomy in the early postoperative period, two groups of cancer patients were examined with their distribution according to clinical diagnosis, gender and age (Table 1).

Table 1

Distribution of cancer patients by clinical diagnosis, gender and age

Clinical diagnosis

Myukhvorykh

Raklivogleenia | 53 | 2 | - | 74 | 2 | 19 | with | 12 | 1

All patients 53 | 2 | - | 14 | 2 | 19 | with | 72 | 1

53 cancer patients with cancer of the left lung were under clinical observation. Age of patients: from 41 to 50 years - 2, from 51 to 60 years - 16, from 61 to 70 years - 22, from 71 to 80 years - 13 cancer patients (see table Mo 1).

The types and nature of surgical interventions are presented in Table 2.

Table 2

Surgical interventions in cancer patients with left lung cancer who received drug infusions

Sorbilact (main group) and Ringer-Locke solution (comparison group) pulmonectomy

Left-sided pulmonectomy was performed in 53 cancer patients with left lung cancer.

The method and volume of operations were determined depending on the localization of the spread and the growth form of the malignant process detected before and during the operations.

The main group - 30 oncological patients with cancer of the left lung after left-sided pulmonectomy surgery received infusion therapy with the use of Sorbilact in a dose of 600.0 ml per day at a rate of 30 drops per minute for 5 days in the early postoperative period.

Comparison group - 23 oncological patients with left lung cancer after left-sided pulmonectomy underwent infusion therapy with Ringer-Locke solution at a dose of 800.0 ml per day.

The study of the influence of the infusion drug Sorbilact and Ringer-Locke solution on the dynamics of the number of erythrocytes, hemoglobin content, leukocyte level, the number of segmented and rod-nucleated neutrophils, eosinophils, lymphocytes, monocytes and the rate of sedimentation of erythrocytes in the blood of operated patients was carried out before the start of infusion therapy, on the first day after intravenous administration, on the second day after intravenous infusions, three days after intravenous infusions, and on the second day after the infusion therapy.

Before the start of infusion therapy, in the first days after surgery in both groups of oncological patients, a decrease in the number of erythrocytes, hemoglobin content, an increase in the level of leukocytes, an increase in the number of rod-nuclear neutrophils and an acceleration of the sedimentation rate of erythrocytes in the blood of operated patients were found.

In cancer patients with left lung cancer, after left-sided pulmonectomy, metabolic and reparative processes develop, which cause changes

Of the hematological indicators, which are aggravated by operative stress, and lead to a decrease in the hemoglobin content, the number of erythrocytes in the blood of operated patients.

The use of the complex infusion drug Sorbilact of multifunctional action immediately after operations in the form of intravenous drip infusions of 600.0 ml per day at the rate of drops per minute for 5 days leads to the normalization of hemoglobin concentration and the number of erythrocytes in the blood of operated patients.

Repeated studies of hematological indicators on the second day after the infusion therapy with Sorbilact showed that in the main group of operated patients, the normalization of the number of erythrocytes and the hemoglobin content in the blood of operated patients was observed (Table Мо 3).

A significant increase in the hemoglobin content in the blood of operated patients is caused by the protein-conserving effect of the high-energy infusion drug Sorbilact, the caloric content of which is 492 kcal (2052 kJ) per 600.0 milliliters. Due to the high energy value of the drug Sorbilact, when administered intravenously to the body of patients, a pronounced protein-sparing effect of the drug is revealed, which eliminates the catabolic breakdown of the internal proteins of the operated organism caused by operative stress, and endogenous proteins are used by the operated organism for the synthesis of hemoglobin, since hemoglobin in erythrocytes consists of globin - a protein with globin chains, which leads to a significant increase in the concentration of hemoglobin in the blood of operated patients and confirms the essence of the task of a useful model.

Table C

The influence of the infusion drug Sorbilact (main group) and Ringer-Locke solution (comparison group) on the hematological parameters of operated patients with left lung cancer after left-sided pulmonectomy (Mat)

Tepatotonn poaznnnya saliva removed |i nn ' Sorbilact p--30 Ringer-Locke p-23

In the comparison group, on the 6th day, the tendency towards normalization of the hemoglobin content and the number of erythrocytes in the blood of the operated patients resumed, but it was significantly less than in the main group.

Normalization of hematological indicators occurred 9 days after the start of intravenous Ringer-Locke solution.

An increase in the number of leukocytes, an increase in the number of rod-shaped neutrophils, and an acceleration of the sedimentation rate of erythrocytes in the blood of operated patients were found in oncological patients with left lung cancer after left-sided pulmonectomy in the early postoperative period.

The use of the multifunctional infusion drug Sorbilact immediately after operations in the form of intravenous drip infusions of 600.0 ml per day at a rate of 30 drops per minute for 5 days leads to the normalization of hematological indicators of operated patients.

Repeated studies of clinical blood analysis on the second day after the use of infusion therapy using the drug Sorbilact showed that in the main group of operated patients there was a normalization of the number of leukocytes, the number of rod-shaped neutrophils and a decrease in the sedimentation rate of erythrocytes in the blood of cancer patients (see Table 3). .

In the comparison group, on the 6th day, the tendency towards the normalization of the number of leukocytes, the number of rod-nuclear neutrophils, and a decrease in the sedimentation rate of erythrocytes was restored, but it was significantly lower than in the main group. Normalization of hematological indicators occurred 9 days after the start of administration of Ringer-Lock solution.

Therefore, the use of infusion therapy in oncological patients with left lung cancer after left-sided pulmonectomy in the early postoperative period helps to accelerate the normalization of hematological parameters on the 6th day after surgical interventions in comparison with Ringer-Locke solution infusions.

The therapeutic effectiveness of the infusion drug Sorbilakt is due to its energetic, detoxifying, intestinal motility stimulating effect and correction of the acid-base state.

So, on the 6th day, after the infusion therapy with the use of the drug Sorbilact, a pronounced clinical effect is observed. In operated patients who received intravenous infusions of the drug Sorbilact, the surgical wound heals faster with primary tension, there are no postoperative complications, operated patients on the 3rd day are discharged from the clinic sooner.

In the comparison group, there was a trend toward improvement in clinical signs on day 6, but significantly less than in the main group. In two oncological patients with cancer of the left lung, after left-sided pulmonectomy, there were signs of insufficiency of the bronchial stump and the need for repeated surgical intervention.

The obtained data confirm that the use of the infusional complex drug Sorbilact of multifunctional action in oncological patients with left lung cancer after left-sided pulmonectomy in the early postoperative period has significant advantages over the use of Ringer-Locke solution, since there is an acceleration of the normalization of clinical signs and there is no insufficiency of the bronchial stump with repeated surgical intervention, which shortens the length of stay of operated patients in inpatient treatment by 3 days.

A specific example of the use of the multi-functional infusion complex drug Sorbilact for the normalization of hematological parameters of a patient with left lung cancer operated on after left-sided pulmonectomy.

Min. T., male, 62 years old, in order to establish a clinical diagnosis in an oncological patient, in addition to an X-ray examination of the lungs, a bronchoscopic examination of the bronchi was performed using a flexible bronchoscope with a biopsy of the tumor, as well as a computer examination of the chest organs, as a result of which a clinical diagnosis of cancer was established left lung The oncology patient underwent a total removal of the left lung. A clinical blood test in the first days after surgery revealed a decrease in the number of erythrocytes and hemoglobin content, an increase in the number of leukocytes, the number of rod-shaped neutrophils, and an acceleration of the erythrocyte sedimentation rate.

Immediately after the operation, the oncology patient was prescribed intravenous drip administration of the complex drug Sorbilact of multifunctional action in a dose of 600.0 ml per day at a rate of 30 drops per minute for 5 days.

Infusion therapy using the drug Sorbilact led to the normalization of the hemoglobin content, the number of erythrocytes, a decrease in the level of leukocytes, the number of rod-shaped neutrophils and a decrease in the rate of sedimentation of erythrocytes in the blood of the operated patient. Wound healing in an oncological patient occurred with primary tension. The condition of the operated patient improved and he was discharged from the clinic in satisfactory condition on the 3rd day sooner than in the comparison group.

Since, when using the multi-functional infusion complex drug Sorbilact, the length of stay of operated patients in inpatient treatment is shortened, thanks to the accelerated normalization of hemoglobin content, the number of erythrocytes, the level of leukocytes, the number of rod-shaped neutrophils in the blood, a decrease in the rate of sedimentation of erythrocytes, as a result of which the immediate results of surgical treatment are improved, which is the essence of the task of a useful model.

Therefore, multiple intravenous administrations of the drug Sorbilact lead to the normalization of hematological indicators of operated patients and prevent the development

Due to insufficiency of the bronchial stump with repeated surgical intervention.

Infusion therapy using the drug Sorbilact has a positive clinical effect, which is expressed in faster healing of postoperative wounds with primary tension. There is no insufficiency of the bronchial stump in operated patients.

Therefore, the use of the multi-functional infusion complex drug Sorbilact for the normalization of hematological parameters of operated patients with left lung cancer after left-sided pulmonectomy allows to reduce the duration of surgical treatment of oncological patients in the early postoperative period, since the immediate results of surgical treatment are improved with the use of the drug Sorbilact, and postoperative complications do not occur , which leads to a reduction in the length of stay of operated patients in the clinic on the 3rd day, which confirms the implementation of the task of a useful model.

The use of the multifunctional infusion drug Sorbilact is characterized by good tolerance and the absence of side effects, infusion therapy does not require expensive drugs, it is based on the use of the domestic drug Sorbilact, which is available in sufficient quantities in Ukrainian pharmacies at an affordable price.

The use of the infusion drug Sorbilact is useful and necessary in medical practice for wide use in infusion therapy of operated patients in intensive care, thoracic and surgical departments of clinics and hospitals.

Claims (1)

USEFUL MODEL FORMULA The use of the multi-functional infusion complex drug Sorbilact for the normalization of hematological indicators of patients operated on for left lung cancer after left-sided pulmonectomy in the early postoperative period, in which the drug is administered immediately after the operations in the form of intravenous drip infusions of 600.0 ml (10.5 ml per kg body weight) per day at a rate of 30 drops per minute for 5 days.